スポンサー企業
アワードについて
サイトライン・ジャパン・アワード2025は今年で4周年を迎えます。
今年で国内開催第4回目となるサイトライン・ジャパン・アワードが、2025年10月21日（火）に東京にて開催決定、数百人の革新的なリーダーが集まり、ネットワーキングや新たな機会の発見、そして医薬品業界における昨年の画期的な成果を振り返る場をご提供いたします。
本アワードは、日本の製薬およびバイオテクノロジー分野における卓越した進歩と革新を称え、世界の医療市場における日本の重要な役割を強調します。アワードへの応募は現在受付中です！皆様からのご応募をお待ちしております。
開催要領
Table prices start from $2580 / 表彰式への参加は１テーブルにつき$2580
Tuesday, October 21, 2025 / 2025年10月21日（火）開催
The Palace Hotel, Tokyo, Japan / パレスホテル東京
There is no fee for entering / アワードへのエントリー（応募）は無料
2024年ハイライトビデオを見る
The Best New Drug Award recognizes excellence in pharmaceutical development. In this category, the judges will be looking for the small-molecule, biological, cell/ gene therapy, digital therapeutic or vaccine product approved in Japan during the qualifying period that represents the best therapeutic advance in its area.
WHO CAN ENTER
Entrants must have played a key role in the development of the nominated product, for example as a sole licensee or co-developer responsible for clinical trials and/or regulatory submissions, and all company members of joint development or joint venture agreements should be disclosed in the application.
This award honors outstanding achievements by biotech companies over the qualifying period. This could be in terms of moving the business from an early stage to a more mature company, signing a transformative deal, taking its first or a major new product towards the market, or raising significant new funds.
WHO CAN ENTER
Company’s highlighting their most significant achievement during the year. Accomplishments in terms of: bringing new products closer to market; raising funds; significant licensing or partnership deals; evidence that management has been able to make difficult decisions to progress the company and its products; using proprietary science or technologies for unmet medical needs; transition from early stage to more mature company.
This Award is to recognize contract research organizations that provide full or specialist services to their clients and which have an office or other base (but not necessarily a head office) either in Japan or the Asia region, including Australia.
Judging will consider the quality and benefits of services and relationships built with clients and will pay particular attention to innovative patient trial recruitment strategies brought to the table.
WHO CAN ENTER
Entrant companies must offer services in Japan, but the achievements listed in the entry form do not necessarily have to be trials or services conducted in Japan (for example, clinical trials conducted in China or Australia are also eligible).
This Award is to recognize contract development manufacturing organizations that provide full or specialist services to their clients and which have an office or other base (but not necessarily a head office) either in Japan or the Asia region, including Australia.
Judging will consider the quality and benefits of services and relationships built with clients and will pay particular attention to innovative services or processes brought to the table.
WHO CAN ENTER
Entrant companies must offer services in Japan, but the achievements listed in the entry form do not necessarily have to be services or manufacturing conducted in Japan (for example, such activities conducted in Asia or Australia are also eligible).
Deals considered here are those that involve the licensing of a particular drug, project or group of R&D assets from one company to another for further development and/ or marketing. (This category does not include more complex, broad partnerships between companies, for example to explore particular therapeutic strategies or mechanisms of action.) The judges will look at all aspects from monetary and strategic value to the benefits they give to both sides.
WHO CAN ENTER
This category does not include more complex, broad partnerships between companies, for example to explore particular therapeutic strategies or mechanisms of action.
This Award seeks to reward successful and creative fundraising by pharma and biotech companies in Japan, which are either privately or publicly owned. The investment can take various forms, including grants and public-private partnership deals, to fundraising from venture capital and private equity partners and initial public offerings. The majority of the new funds should be earmarked for use in drug discovery and/or company development.
WHO CAN ENTER
The basic criterion for this award is the total amount of money raised at one time – for example in a Series A (or later) funding round or through an IPO – but other factors should be considered as well.
The Pharma Company of the Year Award honors outstanding achievement by pharmaceutical companies. This special award is chosen not by the independent judging panel but by our own senior editorial team.
You can nominate your own company but there is no shortlist and the winner is decided by our senior editorial team.
ヘッドラインスポンサー
ICONは世界トップレベルのヘルスケア・インテリジェンスおよびCROです。ダブリンに本社を置き、41,150名以上の従業員を擁し、世界53カ国106の拠点で事業を展開しています。製薬企業、バイオテクノロジー企業、医療機器関連企業、政府・公衆衛生機関に開発・商業化のアウトソーシングサービスを提供し、臨床研究を推進しています。広範な治療領域において、分子から医薬品まで製品開発のライフサイクル全体をカバーしています。
新しい治療法の開発を促進・支援を通じて、人々の健康とよりよい暮らしの実現を目指します。
Global website：https://www.iconplc.com/
日本語website：https://www.iconplc.co.jp/
過去のサイトライン・ジャパン・アワードの様子
サイトライン・ジャパン・アワード 2024
JUL 15, 2024
ヘッドラインスポンサー
